Oragenics, Inc.
Filed with the SEC on · accession 0001493152-26-042843
OGEN filed a 8-K (current report) with the SEC on Sep 16, 2026. Oragenics, Inc. announced that its Chief Medical Officer, James P. The stock moved +2.5% by the first close after the filing.
Oragenics, Inc. announced that its Chief Medical Officer, James P. Kelly, is scheduled to present at the IPAC-RS 2026 Nasal Innovation Forum on September 17, 2026. The company furnished the presentation and a related press release under Regulation FD.
Close before
$0.49
Sep 15, 2026
First close after
+2.54%
$0.50
5 trading days
+6.64%
$0.52
Since filing
-28.40%
$0.35
✦ Ask GOAX AI about this filing — what it means for OGEN, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for OGEN?
Click hereOGEN filed a 8-K (SEC filing). Oragenics, Inc. announced that its Chief Medical Officer, James P. Kelly, is scheduled to present at the IPAC-RS 2026 Nasal Innovation Forum on September 17, 2026. The company furnished the presentation and a related press release under Regulation FD.
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
OGEN closed at $0.49 before the filing and $0.50 on Sep 16, 2026 (+2.54%). Five trading days later: $0.52 (+6.64%).
Get alerts when OGEN files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days